Although L-DOS47’s mechanism of action is not intended to trigger downstream effects via CEACAM6, recent studies have suggested that CEACAM6 is a potential therapeutic target for oncology drugs and may act as a biomarker for tumor progression in cancers, including lung adenocarcinomas (27, 30, 31). Here, CEACAM6 is linked to lung adenocarcinoma.